ReviewGastro hep advances2026
Comparative Efficacy of Herbal Products for Improving Liver Enzymes and Inflammation in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Network Meta-Analysis.
Review in Gastro hep advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) affect adults worldwide and are causes of morbidity. While lifestyle modification remains in first-line therapy, interest has emerged in herbal agents with potential hepatometabolic effects. Evidence synthesis has been limited by heterogeneity in formulations and study quality. We conducted a systematic review and network meta-analysis (NMA) to compare the efficacy of herbal therapies in MASLD/MASH. Methods: Following Preferred Reporting Items for Systematic reviews and Meta-Analyses guidelines and International Prospective Register of Systematic Reviews registration (CRD420251157401), PubMed, Web of Science, EMBASE, and Cochrane were searched through September 2025 for randomized controlled trials evaluating herbal therapies or derivatives in adults with MASLD/MASH. The primary outcomes included alanine aminotransferase, aspartate aminotransferase, gamma-glutamyl transpeptidase, and liver stiffness. Random-effects NMAs estimated mean differences (MDs) with 95% confidence intervals, with treatment ranking using surface under the cumulative ranking curve (SUCRA). Risk of bias was assessed using RoB 2.0, and certainty of evidence using Confidence in NMA. Results: Across 131 randomized trials (n = 9191), several herbal interventions significantly improved liver enzymes. In the NMA for alanine aminotransferase, the greatest reductions were seen with artichoke leaf (MD -28.32; Conclusion: This analysis found that several herbal preparations may improve biochemical markers in MASLD and MASH, though results varied and require cautious interpretation given formulation and regulatory inconsistencies. Future work should focus on the most consistently performing agents: cinnamon, curcumin, silymarin, berberine, artichoke leaf, and
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.